RARA and acute promyelocytic leukemia: These discoveries have led to ATRA being used clinically as an anti-cancer drug; combination treatments that include ATRA have been successful in inducing cancer remission, most notably with acute promyelocytic leukemia (APL), a disease marked by an RARα translocation (43–45).